Evaxion Biotech Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Cash & Equivalents	5.58	13.18	32.17	5.83	9.56	7.43
Cash & Cash Equivalents	5.58	13.18	32.17	5.83	9.56	7.43
Cash Growth	-57.65%	-59.01%	451.35%	-38.97%	28.60%	-
Receivables	1.95	2.79	1.14	1.55	0.58	0.24
Other Current Assets	0.82	1.01	1.4	3.56	0.82	0.71
Total Current Assets	8.35	16.99	34.71	10.95	10.96	8.38
Property, Plant & Equipment	4.34	4.68	5.17	0.22	0.1	0.11
Goodwill and Intangibles	0	0	0.09	0.1	0	0
Other Long-Term Assets	0.2	0.37	0.19	0.69	0.03	0.02
Total Long-Term Assets	4.54	5.04	5.46	1.02	0.13	0.13
Total Assets	12.89	22.03	40.16	11.97	11.08	8.51
Accounts Payable	3.7	2.75	3.88	4.91	1.69	0.78
Current Debt	0.49	0.44	0.44	0.02	0.04	8.64
Other Current Liabilities	2.9	0.57	0	0	0	0
Total Current Liabilities	7.08	3.76	4.32	4.93	1.72	9.42
Long-Term Debt	10.39	9.82	3.25	0	0	0.02
Other Long-Term Liabilities	0.15	0.14	0.15	0	0	0
Total Long-Term Liabilities	10.53	9.96	3.4	0	0	0.02
Total Liabilities	17.62	13.72	7.73	4.93	1.72	9.44
Total Debt	10.87	10.26	3.69	0.02	0.04	8.67
Debt Growth	6.00%	177.91%	18350.00%	-44.44%	-99.58%	-
Retained Earnings	-107.97	-85.85	-50.43	-27.28	-15.81	-6.98
Shareholders' Equity	-4.73	8.3	32.44	7.04	9.36	-0.93
Net Cash / Debt	-5.29	2.93	28.48	5.81	9.52	-1.24
Net Cash / Debt Growth	-	-89.71%	389.78%	-38.95%	-	-
Working Capital	1.27	13.22	30.38	6.02	9.24	-1.04
Book Value Per Share	-1.71	3.58	16.89	3.71	4.94	-

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).